All News

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

There are many substances that are included on the prohibited list for the Tokyo Olympics that are considered standard medications for certain disease states.

The National Institutes of Health grants each entity $14.8 million in funding over the course of 5 years to conduct research into the progressive disease.

Crohn disease causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.

A panel of experts from various settings in the pharmacy field discuss the application of cultural humility and their own experiences when providing culturally appropriate care to underserved or marginalized populations.

These special immune system defense molecules help show which individuals are most at risk of needing intensive care and need to be monitored more closely, new study results show.

With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases

With COVID-19 vaccination clinics still operating and booster doses on the horizon, there continues to be a need for pharmacy technicians as immunizers well into the future.

Lola Fashoyin-Aje, MD, MPH, associate director of Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence, discusses the importance of promoting inclusion of members of racial and ethnic minority groups in cancer drug trials.

Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

The research team analyzed the associations between maternal diabetes before or during pregnancy and the risk of high refractive error (RE), which are conditions in which there is a failure of the eye to properly focus images on the retina.

New artificial intelligence tool can identify tumors at a 97% rate, a year before other methods can diagnose it.

Results from POSEIDON, a randomized open label, phase 3 trial, showed that patients administered 5 cycles of tremelimumab plus durvalumab and chemotherapy over 16 weeks experienced a 23% reduction in the risk of death compared with various chemotherapy options.

Results of a new study show that the vaccines seldomly reach the area that were heavily affected by the pandemic, because of ethnic, racial, and socioeconomic disparities.

Study suggests potentially expanding the use of immunotherapies in the elderly, a population in whom these therapies may be under-prescribed.

Parents are encouraged to either get all immunizations in one health care facility or have a card that documents all the immunizations the child has received.

The Pharmacy Quality Alliance developed the “Medication Access Framework for Quality Measurement” to address the social determinants of health that hinder patient medication access and contribute to poor health outcomes.

The results of a new study show that when coronavirus-infected diabetic mice were injected with an interferon beta, SETDB2 increased and helped decrease the inflammatory cytokines.

Six-point plan outlines strategies to increase national vaccination rates, keep schools open, increase testing and masking access, and to relieve health systems that are overrun with COVID-19 patients.

The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.

Calibrations for the European Randomized Study on Prostate Cancer and Prostate Cancer Prevention Trial predictors can forecast cases across different groups than originally targeted.

Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.

Empagliflozin demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure, compared with placebo.

Investigators used a new animal model to determine how the stem-like T cell can survive and what it looks like over the course of several months of tumor growth.

Concepts could be used in payer-pharmacy value-based arrangements.

A new study explores why individuals who suffer most from the condition have the worse symptoms at night.

Racial or ethnic discrimination can appear in many ways, even as discrimination against someone based on their accent.

Prostate cancers grow slowly and rarely cause any health problems, so without regular screening, it is more difficult to identify any cancer in the prostate.